Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation.
Document Type
Journal Article
Publication Date
11-24-2020
Journal
Contemp Clin Trials
Volume
100
DOI
http://dx.doi.org/10.1016/j.cct.2020.106228
Keywords
Allergies; Anti-IgE; Asthma; Atopic march; Omalizumab; Prevention.
APA Citation
Phipatanakul, W., Mauger, D., Guilbert, T., Bacharier, L., Durrani, S., Jackson, D., Martinez, F., Fitzpatrick, A., Cunningham, A., Kunselman, S., Wheatley, L., Bauer, C., Davis, C., Geng, B., Kloepfer, K., Lapin, C., Liu, A., Pongracic, J., Teach, S. J., Chmiel, J., Gaffin, J., Greenhawt, M., Gupta, M., Lai, P., Lemanske, R., Morgan, W., Sheehan, W., Stokes, J., Thorne, P., Oettgen, H., & Israel, E. (2020). Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation.. Contemp Clin Trials, 100 (). http://dx.doi.org/http://dx.doi.org/10.1016/j.cct.2020.106228
Peer Reviewed
1
Comments
CTSI FUNDED.
This study was supported by grants U01AI126614 , K24AI106822 , K23AI106945 , K23AI104780 , K23AI123517 , from the National Institutes of Health . This work is also supported by the following NIH CTSA Grants and Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Center for Advancing Translational Sciences or the National Institutes of Health : UL1TR000170 , UL1TR001425 , UL1 TR002378 , UL1 TR002535 , UL1TR001876 , UL1TR001422 , UL1TR002529 .